Global
Genetic Disorders Market is expected to register a healthy CAGR of 13.68% in
the forecast period of 2019-2026.
The report contains data from the base year of 2018 and the historic year of
2017. This rise in market value can be attributed to the focus of various
pharmaceutical organizations on development of specialized therapies for
treatment of genetic disorders. Some are the key players taken under coverage
for this study are Amicus Therapeutics, Inc.; Alexion Pharmaceuticals, Inc.;
Sanofi; Takeda Pharmaceutical Company Limited; Vertex Pharmaceuticals
Incorporated; F. Hoffmann-La Roche Ltd; Abbott; Amgen Inc.; ELITechGroup; GW
Pharmaceuticals plc; Thermo Fisher Scientific Inc.; Pfizer Inc.; PerkinElmer
Inc.; AutoGenomics; Bio-Rad Laboratories, Inc.; BioMarin; Sarepta Therapeutics
among others.
Click
to Get Global Genetic Disorders Market Research Sample PDF Copy Here @ https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-genetic-disorders-market
Global
Genetic Disorders Market By Indication (CF, DMD, LSD, PNH), Disease Type
(Alzheimer’s Disease, Cancer, Cystic Fibrosis, Sickle Cell Anemia, DMD,
Thalassemia, Huntington’s Disease, Rare Diseases, Others), Geography (North
America, Europe, Asia-Pacific, South America, Middle East and Africa) –
Industry Trends and Forecast to 2026
Market
Definition: Global Genetic Disorders Market
Genetic
disorders inherited disorders that are passed onto the next-generation by gene
transferring from one generation to the others. These disorders are highly complicated
and rare to treat and require specialized treatments/therapeutics for their
improvements and reduced prevalence amongst patients. These disorders are
generally characterized as life-threating and are progressive in nature with
each disease carrying different symptoms. Currently, the pipeline for treatment
of these disorders is abundant with a number of therapeutics currently in the
late-stage of their trials.
Market
Drivers
- Prevailing cases of genetic and
chronic disease along with the increasing government initiatives in
creating awareness regarding the genetic test and diagnosis; acts as a
driver for the growth of this market
- Significant volume and strength
of pipeline drugs and therapies for genetic disorders; this factor is
expected to boost the growth of the market
- Increasing technological
advancement and R&D funding is another factor which will surge the
market growth
- Increasing prevalence of drugs
being approved in the recent years along with various drugs entering their
last or late-stage of development; this factor is expected to propel the
growth of the market
Market
Restraints
- Significant prevalence and
attrition towards reduction of drugs in clinical trial for genetic
disorders; this factor is expected to hinder the growth of the market
- High costs associated with the
diagnosis and identification of genetic disorders can restrict the market
growth
- Complications related to social
and ethical categories with the utilization of genetic testing; this
factor is expected to act as a restraint in the market growth
Segmentation:
Global Genetic Disorders Market
By
Indication
- Cystic Fibrosis (CF)
- Duchenne Muscular Dystrophy
(DMD)
- Lysosomal Storage Disease (LSD)
- Paraoxysmal Nocturnal
Hemoglobinuria (PNH)
By Disease
Type
- Alzheimer’s Disease
- Cancer
- Cystic Fibrosis
- Sickle Cell Anemia
- Duchenne Muscular Dystrophy
(DMD)
- Thalassemia
- Huntington’s Disease
- Rare Diseases
- Others
By Geography
- North America
- U.S.
- Canada
- Mexico
- Europe
- Germany
- Italy
- U.K.
- France
- Spain
- Netherlands
- Belgium
- Switzerland
- Turkey
- Russia
- Rest of Europe
- Asia-Pacific
- Japan
- China
- India
- South Korea
- Australia
- Singapore
- Malaysia
- Thailand
- Indonesia
- Philippines
- Rest of Asia-Pacific
- South America
- Brazil
- Rest of South America
- Middle East and Africa
- South Africa
- Rest of Middle East and Africa
Order
a Copy of This Research Report @ https://www.databridgemarketresearch.com/inquire-before-buying/?dbmr=global-genetic-disorders-market
Key
Developments in the Market:
- In June 2019, Vertex
Pharmaceuticals Incorporated announced that they had expanded their gene
editing capabilities for the development of novel therapies in Duchenne
Muscular Dystrophy (DMD) and Myotonic Dystotrophy Type 1 (DM1) with the
help of an expansion on the existing collaboration with CRISPR
Therapeutics along with the acquisition of Exonics Therapeutics
- In August 2018, U.S. FDA
announced that they had approved “Galafold (migalastat)”, first approved
oral medication for the treatment of “Fabry” disease having a genetic
mutation responsive towards treatment with “Galafold”. The U.S. FDA has
granted the approval for the drug to Amicus Therapeutics, Inc. having
received accelerated approval pathway with the most extreme reactions
against the drug being headache, throat & nasal irritation, fever,
nausea and urinary tract infection
Competitive
Analysis:
Global
genetic disorders market is highly fragmented and the major players have used
various strategies such as new product launches, expansions, agreements, joint
ventures, partnerships, acquisitions, and others to increase their footprints
in this market. The report includes market shares of genetic disorders market
for Global, Europe, North America, Asia-Pacific, South America and Middle East
& Africa.
Reasons
to Purchase this Report
- Current and future of global
genetic disorders market outlook in the developed and emerging markets
- The segment that is expected to
dominate the market as well as the segment which holds highest CAGR in the
forecast period
- Regions/Countries that are
expected to witness the fastest growth rates during the forecast period
- The latest developments, market
shares, and strategies that are employed by the major market players
Customization
of the Report:
- All segmentation provided above
in this report is represented at country level
- All products covered in the
market, product volume and average selling prices will be included as
customizable options which may incur no or minimal additional cost
(depends on customization)
About Data Bridge Market Research
An absolute way to forecast
what future holds is to comprehend the trend today!
Data Bridge set forth itself
as an unconventional and neoteric Market research and consulting firm with
unparalleled level of resilience and integrated approaches. We are determined
to unearth the best market opportunities and foster efficient information for
your business to thrive in the market. Data Bridge endeavors to provide
appropriate solutions to the complex business challenges and initiates an
effortless decision-making process. Data Bridge is an aftermath of sheer wisdom
and experience which was formulated and framed in the year 2015 in Pune.
Contact:
Data Bridge Market Research
US: +1 888 387 2818
UK: +44 208 089 1725
Hong Kong: +852 8192 7475